Literature DB >> 9000677

Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage.

G W Byrne1, K R McCurry, M J Martin, S M McClellan, J L Platt, J S Logan.   

Abstract

We characterize a line of transgenic pigs that express the human complement-regulatory proteins human CD59 and human decay-accelerating factor. These genes, under the control of heterologous promoters, are expressed in a variety of organs, including the vasculature of the heart, kidney, and liver. We demonstrate that moderate levels of these gene products are sufficient to protect peripheral blood cells from human or baboon complement. Using pig to baboon heterotopic heart transplants, we show that expression of these proteins is sufficient to block the complement-mediated damage that is the hallmark of such xenografts, when nontransgenic organs are used. These results indicate that there is significant species specificity of intrinsic complement regulatory protein function. This specificity is evident in transgenic organs in which low levels of human CD59 and human decay-accelerating factor expression significantly effect the humoral immune response that causes xenograft rejection. This result suggests that transgenic organs with high levels of human complement-regulatory protein expression will be sufficient to alleviate the humoral immunological barriers that currently block the use of xenogeneic organs for human transplantation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9000677     DOI: 10.1097/00007890-199701150-00027

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  40 in total

Review 1.  Xenotransplantation--2000.

Authors:  M J Goddard; J E Foweraker; J Wallwork
Journal:  J Clin Pathol       Date:  2000-01       Impact factor: 3.411

2.  Complement regulation at the molecular level: the structure of decay-accelerating factor.

Authors:  P Lukacik; P Roversi; J White; D Esser; G P Smith; J Billington; P A Williams; P M Rudd; M R Wormald; D J Harvey; M D M Crispin; C M Radcliffe; R A Dwek; D J Evans; B P Morgan; R A G Smith; S M Lea
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-20       Impact factor: 11.205

Review 3.  Genetic modification of xenografts.

Authors:  J L Platt
Journal:  Curr Top Microbiol Immunol       Date:  2003       Impact factor: 4.291

Review 4.  Current status of pig heart xenotransplantation.

Authors:  Muhammad M Mohiuddin; Bruno Reichart; Guerard W Byrne; Christopher G A McGregor
Journal:  Int J Surg       Date:  2015-08-28       Impact factor: 6.071

5.  Rejection severity directly correlates with myocyte apoptosis in pig-to-baboon cardiac xenotransplantation.

Authors:  Joel G R Weaver; Christopher G A McGregor; Henry D Tazelaar; Andrew D Badley
Journal:  J Heart Lung Transplant       Date:  2005-07       Impact factor: 10.247

6.  Upregulation of CD59: potential mechanism of accommodation in a large animal model.

Authors:  Adam D Griesemer; Masayoshi Okumi; Akira Shimizu; Shannon Moran; Yoshinori Ishikawa; Justin Iorio; J Scott Arn; Kazuhiko Yamada
Journal:  Transplantation       Date:  2009-05-15       Impact factor: 4.939

Review 7.  Antibody-mediated xenograft injury: mechanisms and protective strategies.

Authors:  Richard N Pierson
Journal:  Transpl Immunol       Date:  2009-04-17       Impact factor: 1.708

Review 8.  The future use of complement inhibitors for the treatment of neurological diseases.

Authors:  E G McGeer; P L McGeer
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

Review 9.  Recent advances in the immunology of xenotransplantation.

Authors:  T Takahashi; S Saadi; J L Platt
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

10.  Anti-inflammatory and anticoagulant effects of transgenic expression of human thrombomodulin in mice.

Authors:  S Crikis; X M Zhang; S Dezfouli; K M Dwyer; L M Murray-Segal; E Salvaris; C Selan; S C Robson; H H Nandurkar; P J Cowan; A J F d'Apice
Journal:  Am J Transplant       Date:  2010-01-06       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.